Clinical trial
An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons
NCT01054573 is registered in ClinicalTrials.gov with Janssen Infectious Diseases BVBA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2010
- Completion date
- May 31, 2012
- Enrollment
- 90 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.